Cibc World Markets Corp bought a new stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 13,065 shares of the biopharmaceutical company's stock, valued at approximately $393,000.
Several other hedge funds have also made changes to their positions in TGTX. Blue Trust Inc. lifted its holdings in TG Therapeutics by 24.5% in the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock valued at $57,000 after acquiring an additional 371 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of TG Therapeutics by 512.5% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after purchasing an additional 1,594 shares during the period. Jones Financial Companies Lllp increased its position in shares of TG Therapeutics by 460.7% during the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 1,737 shares during the last quarter. Synergy Asset Management LLC purchased a new stake in TG Therapeutics in the 4th quarter valued at about $75,000. Finally, GAMMA Investing LLC lifted its position in TG Therapeutics by 562.4% in the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock valued at $77,000 after buying an additional 2,171 shares during the last quarter. Hedge funds and other institutional investors own 58.58% of the company's stock.
TG Therapeutics Stock Down 1.4 %
Shares of NASDAQ TGTX traded down $0.59 during midday trading on Thursday, hitting $40.20. The company's stock had a trading volume of 1,308,186 shares, compared to its average volume of 2,975,993. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The firm has a market capitalization of $6.31 billion, a price-to-earnings ratio of -401.96 and a beta of 2.30. The business's fifty day simple moving average is $33.95 and its two-hundred day simple moving average is $30.11. TG Therapeutics, Inc. has a 1 year low of $12.93 and a 1 year high of $43.32.
TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. The company had revenue of $108.19 million for the quarter, compared to analyst estimates of $100.67 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. On average, equities analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current year.
Insiders Place Their Bets
In related news, CFO Sean A. Power sold 10,021 shares of the company's stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $28.53, for a total transaction of $285,899.13. Following the sale, the chief financial officer now directly owns 660,611 shares in the company, valued at approximately $18,847,231.83. This represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.50% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on the stock. HC Wainwright reiterated a "buy" rating and set a $55.00 price target on shares of TG Therapeutics in a research report on Tuesday, March 4th. StockNews.com raised TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $40.67.
Get Our Latest Research Report on TGTX
TG Therapeutics Company Profile
(
Free Report)
TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.
See Also
Before you consider TG Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TG Therapeutics wasn't on the list.
While TG Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
